POSTN and asthma: The overall reduction in asthma exacerbation rates in this study was better than those observed in the Phase 3 trials in adults with asthma treated with lebrikizumab: in the LAVOLTA studies, biomarker‐high patients (periostin ≥50 ng/ml, blood eosinophil count ≥300 cells/μl, or both) treated with lebrikizumab 125 and 37.5 mg achieved 30% and 51% reductions, respectively (LAVOLTA I), or a 26% reduction (LAVOLTA II; both doses).19